GMP production of CG01 made available for preclinical studies planned to enable First in Human study
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 STOCKHOLM — CombiGene AB (‘CombiGene’) and Spark Therapeutics (‘Spark‘), a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company...
BioStock: CombiGene’s CEO about the path to the first clinical trial
News 2021 2021 2020 2019 2018 2017 2016 2015 "CombiGene recently strengthened its gene therapy project CG01 in the best possible way when it signed an exclusive, global collaboration and licensing agreement with Spark Therapeutics worth over 320...
CombiGene and Spark Therapeutics plan to expand the clinical development program to include the U.S. as well as Europe
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 The clinical development program for CombiGene’s CG01 project, which is being developed to treat drug-resistant focal epilepsy, was originally planned to be performed in Europe, CombiGenes home...
CombiGene’s CEO Jan Nilsson describes how the collaboration and licensing agreement with Spark Therapeutics creates new business development opportunities at Stora Aktiedagen Stockholm November 30, at 16.30
News 2021 2021 2020 2019 2018 2017 2016 2015 The agreement provides Spark with the exclusive world-wide license to develop, manufacture and commercialize CG01. Under the terms of agreement, CombiGene is eligible to receive up to $328.5 million...
Article in BioStock November 2021: CombiGene gears up for clinical studies and expanded pipeline
News 2021 2021 2020 2019 2018 2017 2016 2015 Article >> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business...
CombiGene AB (publ): Nominating committee
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 The nominating committee has been constituted in accordance with the resolution adopted by the annual general meeting (“AGM”) 2021 The AGM 2021 resolved that a nominating committee should be...
Interim Report January – September 2021
Financial reports 2021 2021 2020 2019 2018 2017 2016 2015 2014 2013 Interim Report January – September 2021 >> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a...
CombiGene’s Karin Agerman talks about ATMP in new NLS article
News 2021 2021 2020 2019 2018 2017 2016 2015 In a new NLS article, Karin Agerman, Chief Research & Development Officer at CombiGene, and Tony Hitchcock, Technical Director at Cobra Biologics, a Charles River Company, explores the effects of the...
CEO Jan Nilsson talks about new opportunities for CombiGene in a major interview with BioStock
News 2021 2021 2020 2019 2018 2017 2016 2015 To the article november 4 2021 >> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies....
November 17-18, CombiGene’s Project Manager CMC Martin Linhult to present at AdBIOPRO’s workshop Bioproduction of Therapeutic Biologics in Stockholm.
News 2021 2021 2020 2019 2018 2017 2016 2015 CombiGene’s Project Manager CMC Martin Linhult has been invited to speak at AdBIOPRO’s workshop Bioproduction of Therapeutic Biologics in Stockholm, November 17-18, 2021, to present and discuss CMC...
CombiGene’s Horizon 2020 project successfully completed – Paved the way for the agreement with Spark Therapeutics
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 On May 15, 2018, Horizon 2020, the EU framework for research and development, announced that it had decided to invest EUR 3.36 million in CombiGene's continued development of the gene therapy...
A big thank you to CombiGene’s shareholders! You’ve made CombiGene’s amazing journey possible!
News 2021 2021 2020 2019 2018 2017 2016 2015 This is an article taken from INGENEIOUS 1 - 2021Read the whole INGENEIOUS here » It is no secret that drug development takes a long time, requires considerable financial resources, and contains a great...
On November 30, 2021, CEO Jan Nilsson will present CombiGene’s latest progress at Stora Aktiedagen Stockholm
News 2021 2021 2020 2019 2018 2017 2016 2015 To Aktiedagen >> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s...
CombiGene’s scientific founders talks about the agreement with Spark in a new interview in BioStock
News 2021 2021 2020 2019 2018 2017 2016 2015 To the article in BioStock october 26 2021 >> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel...
CombiGene’s Chairman Bert Junno comments on the agreement with Spark
News 2021 2021 2020 2019 2018 2017 2016 2015 This is an article taken from INGENEIOUS 1 - 2021Read the whole INGENEIOUS here » What are your first spontaneous comments on the deal with Spark? "First of all, the deal is extremely gratifying – and...
CombiGene’s agreement with Spark has a major impact in Analysguiden’s updated analysis
News 2021 2021 2020 2019 2018 2017 2016 2015 CombiGene's collaboration and licensing agreement with the world-leading gene therapy company Spark Therapeutics has major impact in Analysguiden’s updated analysis of the company. In the analysis, the target...
Ingeneious #3 2021, News from CombiGene
Genevägen 2021 2021 2020 2019 2018 2017 Read CombiGene´s newsletter Ingeneious in EnglishTo Ingeneious >> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel...
22-24 March 2022, CombiGene’s Project Manager CMC Martin Linhult to present at Bioprocessing Summit Europe, Barcelona
2021 2020 2019 2018 2017 2016 2015 CombiGene’s Project Manager CMC Martin Linhult has been invited to speak at Bioprpocessing Summit Europe, Barcelona, March 22-24, 2022 to present and discuss CMC (Chemistry, Manufacturing, and Control) aspects for gene...
April 11 – 13, 2022, CombiGene’s Project Manager CMC Martin Linhult to present at Gene Therapy Summit in Boston, MA
2021 2020 2019 2018 2017 2016 2015 CombiGene’s Project Manager CMC Martin Linhult has been invited to speak at Gene Therapy Summit in Boston, MA, April 11 - 13, 2022 to present and discuss CMC (Chemistry, Manufacturing, and Control) aspects for gene...
Jan Nilsson presents CombiGene on Vator Securities Healthcare Innovation Summit october 7
Nyheter 2021 2021 2020 2019 2018 2017 2016 2015 The presentation >> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s...
BioStock: CombiGene in billion-dollar deal with Spark Therapeutics
2021 2020 2019 2018 2017 2016 2015 BioStock october 12 2021 >> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business...
CombiGene and Spark Therapeutics enter exclusive, global licensing agreement for gene therapy candidate CG01
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 STOCKHOLM — CombiGene AB (‘CombiGene’ or the ‘Company’) and Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company...
October 7, Vator Securities Healthcare Innovation Summit
2021 2020 2019 2018 2017 2016 2015 Jan Nilsson will present CombiGene on Vator Securities Healthcare Innovation Summit vatorsecurities.se/event/vator-securities-healthcare-innovation-summit/ Om CombiGene CombiGenes vision är att erbjuda patienter som...
The Analysis Guide adjusts the target price for CombiGene to SEK 21
2021 2020 2019 2018 2017 2016 2015 Here's how Thomas Nilsson writes in his latest analysis of CombiGene:As the company's epilepsy project CG01 enters phase 1/2 studies in 2022, we have recently raised the probability of launch to 15%. As the company enters...
BioStock 27 august: CombiGene comments the international patent application
Interviews and presentations 2021 2021 2020 2019 2018 2017 2016 2015 The gene therapy company CombiGene announced yesterday that it has submitted a PCT application to protect the vectors developed within the lipodystrophy project CGT2. This application...
CombiGene applies for international patent protection for the vectors developed within the CGT2 project
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 CombiGene announces today that the company has submitted a so-called PCT application to protect the vectors being developed within the lipodystrophy project CGT2. The Patent Cooperation Treaty (PCT)...
28/8-1/9 Merab Kokaia speaks at The International Epilepsy Congress
Interviews and presentations 2021 2021 2020 2019 2018 2017 2016 2015 Professor Merab Kokaia, one of CombiGene's scientific founders, speaks at The International Epilepsy CongressThe 34th edition of The International Epilepsy Congress is held from 28 August...
Interim Report January – June 2021
Financial reports 2021 2021 2020 2019 2018 2017 2016 2015 2014 2013 Interim Report January – June 2021>> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life...
Biostock: CombiGene’s CEO on this summer’s news
2021 2020 2019 2018 2017 2016 2015 "The gene therapy company CombiGene ended July with two significant pieces of news. Firstly, the company has started GMP production of the drug candidate CG01 for the first clinical study that begin next year. Secondly,...
Patent approved in the U.S. and Russia for CombiGenes gene therapy candidate CG01
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 CombiGene's gene therapy candidate CG01, which is being developed for the treatment of drug-resistant focal epilepsy, has received patent protection in the U.S., the world’s largest pharmaceutical...
CombiGene initiates GMP production of CG01 for the first-in-human study
2021 2020 2019 2018 2017 2016 2015 CombiGene, in collaboration with its manufacturing partner, the leading AAV gene therapy contract manufacturer Viralgen, has today started GMP production of the drug candidate CG01, a gene therapy developed for the...
Article in BioStock: CombiGene announces several milestones for CG01
2021 2020 2019 2018 2017 2016 2015 Lund-based gene therapy company CombiGene continues to advance its main project CG01 ahead of the phase I studies scheduled to begin next year. The company is now ready for GMP production of drug substance and has also...
CombiGene and Neurochase begin work to optimize the administration of CG01
2021 2020 2019 2018 2017 2016 2015 CombiGene's epilepsy project CG01 continues to advance towards the first clinical trial scheduled to begin in 2022. An important step on the way to clinical studies is optimizing the administration of CG01. CombiGene has...
GMP plasmids released – Ready to start GMP production of CG01
2021 2020 2019 2018 2017 2016 2015 Cobra Biologics (Cobra), the gene therapy division of Cognate BioServices, a Charles River Laboratories International, Inc. company and CombiGene AB (publ) (CombiGene), the leading gene therapy company in the Nordic...
On June 8-10, CombiGene’s Preclinical Project Manager Annika Ericsson will participate in Next Generation Gene Therapy Vectors.
2021 2020 2019 2018 2017 2016 2015 ”I look forward to an exciting conference on the next generation of gene therapy vectors and to discuss limitations that current gene therapy vectors have, including immunogenicity, toxicity and safety”, says Annika....
Record date for reverse share split in CombiGene
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 The Board of Directors of CombiGene AB (publ) ("CombiGene") has resolved that the record date for the reverse share split shall be 8 June. Through the reverse share split, twenty (20) existing shares...
The EU continues to invest in CombiGene
2021 2020 2019 2018 2017 2016 2015 This is an article from Ingeneious number 2 2021.Read the whole Ingeneious here >> CombiGene’s epilepsy project CG01 has already been granted EUR 3.36 million by the EU programme Horizon 2020. Now the EU is...
Gunilla Lundmark new board member of CombiGene
News 2021 2021 2020 2019 2018 2017 2016 2015 At CombiGene’s Annual General Meeting, Gunilla Lundmark was elected as new member of the Board of Directors. Gunilla is an entrepreneur through and through, and has 25 years of experience from leading positions...
First in human study within reach
News 2021 2021 2020 2019 2018 2017 2016 2015 This is an article from Ingeneious number 2 2021.Read the whole Ingeneious here >> A lot has happened at CombiGene during the first months of 2021 and when Ingeneious gets the opportunity to talk to...
Bulletin from the annual general meeting of CombiGene AB (publ)
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 The following resolutions were passed at the annual general meeting (the “AGM”) of CombiGene AB (publ) (“CombiGene”) on 25 May 2021. Adoption of income statement and balance sheet and discharge from...
CombiGene’s CEO Jan Nilsson is one of the speakers as “The Future of Swedish and Danish Life Science” celebrates its 10th anniversary
News 2021 2021 2020 2019 2018 2017 2016 2015 On September 2, Jan Nilsson will present his experiences within gene therapy under the heading Gene Therapy, an important tool for precision medicine.Here you will find information about the...
Ingeneious #2 2021, News from CombiGene
Ingeneious 2021 2021 2020 2019 2018 2017 Read CombiGene´s newsletter Ingeneious in EnglishTo Ingeneious >> CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement...
Interim Report January – March 2021
Financial reports 2021 2021 2020 2019 2018 2017 2016 2015 2014 2013 Interim Report January – March 2021 >> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life...
Biostock summarizes CombiGene’s progress on the way to the first in human study
Interviews and presentations 2021 2021 2020 2019 2018 2017 2016 2015 Biostock summarizes CombiGene's progress on the way to the first in human study https://www.biostock.se/en/combigene-paved-the-way-for-2022-during-2020/ 2021 » News » Regulatory news...
CombiGene annual report 2020
Financial reports 2021 2021 2020 2019 2018 2017 2016 2015 2014 2013 Annual report 2020>> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene...
Notice of annual general meeting in CombiGene
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. The shareholders of CombiGene AB (publ) are hereby summoned to...
30 april, CombiGene’s Karin Agerman is one of the hosts at ATMP world tour
News 2021 2021 2020 2019 2018 2017 2016 2015 On Friday April 30, CombiGene’s Chief Research & Development Officer Karin Agerman will host a discussion on manufacturing of gene therapies for pre-clinical and clinical studies at the ATMP world tour....
Articel in BioStock: CombiGene raised 75MSEK through rights issue
News 2021 2021 2020 2019 2018 2017 2016 2015 This week, CombiGene announced the outcome of a rights issue, which was was resolved by the board of directors on 8 March 2021 based on the authorisation from the annual general meeting held on 29 June 2020....
CombiGene announces outcome in rights issue
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 The information in this press release is not intended for publication, public release or distribution, directly or indirectly, in or into the USA, Canada, Japan, Australia, Hong Kong, New Zealand,...
Today, CombiGene Celebrates the World Lipodystrophy Day
News 2021 2021 2020 2019 2018 2017 2016 2015 Currently, there is no cure for lipodystrophy, and just the secondary complications can be treated. Lipodystrophy is a rare and very serious disease. CombiGene continues to develop the pre-clinical work in the...
About CombiGene
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.
The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.